171 related articles for article (PubMed ID: 18322041)
1. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease.
Ishii H; Kumada Y; Toriyama T; Aoyama T; Takahashi H; Yamada S; Yasuda Y; Yuzawa Y; Maruyama S; Matsuo S; Matsubara T; Murohara T
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1034-40. PubMed ID: 18322041
[TBL] [Abstract][Full Text] [Related]
2. Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients.
Ishii H; Kumada Y; Toriyama T; Aoyama T; Takahashi H; Tanaka M; Kamoi D; Kawamura Y; Yamada S; Hayashi M; Yasuda Y; Yuzawa Y; Maruyama S; Matsuo S; Matsubara T; Murohara T
Clin Ther; 2010 Jan; 32(1):24-33. PubMed ID: 20171408
[TBL] [Abstract][Full Text] [Related]
3. Nitinol stenting improves primary patency of the superficial femoral artery after percutaneous transluminal angioplasty in hemodialysis patients: a propensity-matched analysis.
Kawamura Y; Ishii H; Aoyama T; Tanaka M; Takahashi H; Kumada Y; Toriyama T; Murohara T
J Vasc Surg; 2009 Nov; 50(5):1057-62. PubMed ID: 19782527
[TBL] [Abstract][Full Text] [Related]
4. Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease.
Ishii H; Aoyama T; Takahashi H; Kumada Y; Kamoi D; Sakakibara T; Umemoto N; Suzuki S; Tanaka A; Ito Y; Murohara T
J Cardiol; 2016 Feb; 67(2):199-204. PubMed ID: 26074442
[TBL] [Abstract][Full Text] [Related]
5. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol.
Soga Y; Iida O; Hirano K; Suzuki K; Yokoi H; Nobuyoshi M
Catheter Cardiovasc Interv; 2012 Mar; 79(4):541-8. PubMed ID: 21805619
[TBL] [Abstract][Full Text] [Related]
6. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.
Iida O; Yokoi H; Soga Y; Inoue N; Suzuki K; Yokoi Y; Kawasaki D; Zen K; Urasawa K; Shintani Y; Miyamoto A; Hirano K; Miyashita Y; Tsuchiya T; Shinozaki N; Nakamura M; Isshiki T; Hamasaki T; Nanto S;
Circulation; 2013 Jun; 127(23):2307-15. PubMed ID: 23652861
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of percutaneous transluminal angioplasty in chronic haemodialysis patients with peripheral arterial disease.
Kumada Y; Aoyama T; Ishii H; Tanaka M; Kawamura Y; Takahashi H; Toriyama T; Aoyama T; Yuzawa Y; Maruyama S; Matsuo S; Murohara T
Nephrol Dial Transplant; 2008 Dec; 23(12):3996-4001. PubMed ID: 18596131
[TBL] [Abstract][Full Text] [Related]
8. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
Tsuchikane E; Fukuhara A; Kobayashi T; Kirino M; Yamasaki K; Kobayashi T; Izumi M; Otsuji S; Tateyama H; Sakurai M; Awata N
Circulation; 1999 Jul; 100(1):21-6. PubMed ID: 10393676
[TBL] [Abstract][Full Text] [Related]
9. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty.
Take S; Matsutani M; Ueda H; Hamaguchi H; Konishi H; Baba Y; Kawaratani H; Sugiura T; Iwasaka T; Inada M
Am J Cardiol; 1997 Apr; 79(8):1097-9. PubMed ID: 9114771
[TBL] [Abstract][Full Text] [Related]
10. Intragraft pressures predict outcomes in hemodialysis patients with graft outflow lesions undergoing percutaneous transluminal angioplasty.
Lai CC; Chung HM; Tsai HL; Mar GY; Tseng CJ; Liu CP
Catheter Cardiovasc Interv; 2010 Aug; 76(2):206-11. PubMed ID: 20665863
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
[TBL] [Abstract][Full Text] [Related]
12. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S;
J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
[TBL] [Abstract][Full Text] [Related]
13. Calcium channel antagonists reduce restenosis after percutaneous transluminal angioplasty of an arteriovenous fistula in hemodialysis patients.
Doi S; Masaki T; Shigemoto K; Harada S; Yorioka N
Ther Apher Dial; 2008 Jun; 12(3):232-6. PubMed ID: 18503701
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of primary angioplasty and primary stenting of central venous stenosis in hemodialysis patients.
Bakken AM; Protack CD; Saad WE; Lee DE; Waldman DL; Davies MG
J Vasc Surg; 2007 Apr; 45(4):776-83. PubMed ID: 17398386
[TBL] [Abstract][Full Text] [Related]
15. Prospective, randomized study of cutting balloon angioplasty versus conventional balloon angioplasty for the treatment of hemodialysis access stenoses.
Saleh HM; Gabr AK; Tawfik MM; Abouellail H
J Vasc Surg; 2014 Sep; 60(3):735-40. PubMed ID: 24794277
[TBL] [Abstract][Full Text] [Related]
16. Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients.
Shiohira S; Yoshida T; Sugiura H; Yoshida S; Mitobe M; Shimada K; Ohba T; Tsuchiya K; Kabaya T; Nitta K
Clin Exp Nephrol; 2011 Dec; 15(6):893-9. PubMed ID: 21773691
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
Hiatt WR; Money SR; Brass EP
J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
[TBL] [Abstract][Full Text] [Related]
18. Role of Cilostazol Therapy in Hemodialysis Patients with Asymptomatic Peripheral Arterial Disease: A Retrospective Cohort Study.
Lim PS; Jeng Y; Wu MY; Pai MA; Wu TK; Chen CH
Biomed Res Int; 2016; 2016():8236903. PubMed ID: 27747241
[No Abstract] [Full Text] [Related]
19. Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery.
Iida O; Nanto S; Uematsu M; Morozumi T; Kotani J; Awata M; Onishi T; Ito N; Oshima F; Minamiguchi H; Kitakaze M; Nagata S
Circ J; 2005 Oct; 69(10):1256-9. PubMed ID: 16195627
[TBL] [Abstract][Full Text] [Related]
20. Cilostazol and peripheral arterial disease.
Pearce L; Ghosh J; Counsell A; Serracino-Inglott F
Expert Opin Pharmacother; 2008 Oct; 9(15):2683-90. PubMed ID: 18803454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
